

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EXTRAWELL PHARMACEUTICAL HOLDINGS LIMITED

精優藥業控股有限公司*

(Incorporated in Bermuda with limited liability)

(Stock Code: 00858)

POLL RESULTS OF SPECIAL GENERAL MEETING HELD ON 28 JUNE 2023

References are made to notice of special general meeting (the “SGM”) and the circular (the “Circular”) both dated 12 June 2023 published by Extrawell Pharmaceutical Holdings Limited (the “Company”). Unless the context otherwise requires, terms defined in this announcement shall have the same meanings as those defined in the Circular.

POLL RESULTS OF THE SGM

The Company announces the poll results of the resolution proposed at the SGM held on 28 June 2023 as follows:

Ordinary Resolution		Number of Votes (%) (Note)	
		For	Against
1.	To approve, ratify and confirm the third amendment deed (“Third Amendment Deed”) and the deed of waiver (“Deed of Waiver”) both dated 28 April 2023 entered into between the Company and Innovative Pharmaceutical Biotech Limited (“Innovative”) in relation to the amendment of certain terms and conditions (“Third Amendments”) of the convertible bonds issued by Innovative to the Company in the principal amount of HK\$715,000,000 and all transactions contemplated thereunder including the Third Amendments and authorize the directors of the Company to do all such acts and things (including, without limitation, signing, executing (under hand or under seal) to the Third Amendment Deed and the Deed of Waiver) to give effect to the Third Amendments.	348,492,540 (100%)	0 (0%)
The resolution was duly passed as an ordinary resolution.			

Note: The number of votes and percentage of the voting are based on the total number of Shares held by the Shareholders who voted at the SGM in person, by authorized corporate representative(s) or by proxies.

As at the date of the SGM, the total number of Shares in issue was 2,390,000,000. As stated in the Circular, Dr. Mao Yumin holding approximately 7.94% (189,920,000 Shares) of the Shares in issue was required to abstain from voting on the proposed ordinary resolution at the SGM. Accordingly, the total number of Shares entitling the Shareholders to attend and vote for or against on the resolution at the SGM was 2,200,080,000 Shares, representing approximately 92.06% of the total number of Shares in issue as at the time of the SGM. No Shareholder was entitled to attend and vote only against the resolution at the SGM.

Tricor Tengis Limited, the Company's Hong Kong branch share registrar and transfer office, acted as the scrutineer for the vote-taking at the SGM.

The Company's directors, Ms Wong Sau Kuen and Mr. Cheng Yong attended the SGM in person, and Dr. Xie Yi, Dr. Lou Yi, Mr. Fang Lin Hu, Ms. Jin Song and Dr. Guo Yi attended the SGM by electronic means.

By order of the Board
Extrawell Pharmaceutical Holdings Limited
Xie Yi
Chairman

Hong Kong, 28 June 2023

As at the date of this announcement, the executive directors are Dr. Xie Yi, Mr. Cheng Yong, Dr. Lou Yi and Ms. Wong Sau Kuen, and the independent non-executive directors are Mr. Fang Lin Hu, Ms. Jin Song and Dr. Guo Yi.

* *For identification purpose only*